BCL-2 antisense (G3139) plus docetaxel for treatment of progressive androgen-independent prostate cancer

Authors

Publication/Presentation Date

4-2001

Volume

37

Issue

6

First Page

218

Last Page

219

Disciplines

Business Administration, Management, and Operations | Health and Medical Administration | Management Sciences and Quantitative Methods

Department(s)

Administration and Leadership

Document Type

Article

Share

COinS